We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03181087
Recruitment Status : Withdrawn (The pandemic resulted in no enrollments.)
First Posted : June 8, 2017
Last Update Posted : December 21, 2022
Sponsor:
Information provided by (Responsible Party):
Zhengping Liu, MD, Maternal and Child Health Hospital of Foshan

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety of umbilical cord mesenchymal stem cell local intramuscular injection for treatment of uterine scars by a prospective, single-center, open, and single-arm clinical trial.

Condition or disease Intervention/treatment Phase
Uterine Scar Other: Umbilical cord MSCs Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Single-arm, Open Study of the Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars
Estimated Study Start Date : December 11, 2021
Estimated Primary Completion Date : October 31, 2022
Estimated Study Completion Date : May 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety Scars

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Umbilical cord MSCs Group
1*10^7 Umbilical cord Mesenchymal Stem Cells (MSCs)
 Other: Umbilical cord MSCs
Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety evaluation through vital signs, the results of clinical lab tests and adverse events [ Time Frame: 6 months post treatment ]
    Safety evaluation through vital signs, the results of clinical lab tests and adverse events.


Secondary Outcome Measures :
  1. Number of participants with uterine niche [ Time Frame: 6 months post treatment ]
    The niche is defined as a triangular anechoic area at the presumed site of incision in the uterus by transvaginal utrasonography.

  2. Change of uterine scar thickness [ Time Frame: 6 weeks, 3 and 6 months post treatment ]
    The scar thickness be measured using a transvaginal utrasonography

  3. Change of uterine scar area [ Time Frame: 6 weeks, 3 and 6 months post treatment ]
    The scar area will be measured using a transvaginal utrasonography

  4. Number of participants with endometritis [ Time Frame: 6 months post treatment ]
    Endometritis is defined as the presence of at least two of the following signs with no other recognized cause: fever (temperature of at least 38℃), abdominal pain, uterine tenderness, or purulent drainage from the uterus.

  5. Number of participants with wound infection [ Time Frame: 6 months post treatment ]
    Wound infection is defined as the presence of either superficial or deep incisional surgical-site infection characterized by cellulitis or erythema and induration around the incision or purulent discharge from the incision site with or without fever and included necrotizing fasciitis.

  6. Immunoglobulin concentrations in breast milk and serum [ Time Frame: 6 weeks, 3 and 6 months post treatment ]
    Breast milk and serum immunoglobulin (IgG, IgA, IgM) and the complement (C3, C4) are detected by transmission immune turbidity method using automatic biochemical analyzer.

  7. Adverse events occurrence [ Time Frame: 6 months post treatment ]
    Adverse events will be evaluated since the baseline visit until 6 months after the end of the treatment.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Primiparous women receiving cesarean delivery
  • Ages between 21-35 years
  • Gestation ages ≥ 37 weeks and < 42 weeks
  • Willing to comply with study dosing and completed the entire course of the study
  • Willing to give and sign an informed consent form and a photographic release form

Exclusion Criteria:

  • Fibroids
  • Placenta previa
  • Placenta abruption
  • Multiple gestation
  • Antepartum hemorrhage
  • Preeclampsia/Eclampsia
  • Hepatic or renal dysfunction
  • Any systemic uncontrolled disease
  • Inability to provide consent
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03181087


Locations
Layout table for location information
China, Guangdong
Maternal and Child Health Hospital of Foshan
Foshan, Guangdong, China, 528000
Sponsors and Collaborators
Maternal and Child Health Hospital of Foshan
Investigators
Layout table for investigator information
Principal Investigator: Zhengping Liu, MD Maternal and Child Health Hospital of Foshan
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Zhengping Liu, MD, Director, Maternal and Child Health Hospital of Foshan
ClinicalTrials.gov Identifier: NCT03181087    
Other Study ID Numbers: MCHHFoshan-1701
First Posted: June 8, 2017    Key Record Dates
Last Update Posted: December 21, 2022
Last Verified: December 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhengping Liu, MD, Maternal and Child Health Hospital of Foshan:
Mesenchymal Stem Cells
Cesarean Section
Uterine Scar
Additional relevant MeSH terms:
Layout table for MeSH terms
Cicatrix
Fibrosis
Pathologic Processes